Global Lung Cancer Diagnostics Treatment Market, 2025-2035

Description

List of Tables

Global Lung Cancer Diagnostics Treatment Market Size, Share & Trends Analysis by Type (Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC)), By Diagnosis Type (Imaging Tests, Biopsy, and Molecular Testing), By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By End-User (Hospitals, Diagnostic Laboratories, Specialty Clinics / Cancer Centers, and Others), Forecast Period (2026-2035)

Industry Overview

Lung cancer diagnostics treatment market was valued at $30.3 billion in 2025 and is projected to reach $52.7 billion by 2035, growing at a CAGR of 5.8% during the forecast Period (2026-2035). The market is experiencing steady growth, driven by increasing lung cancer prevalence and rising demand for early detection and effective therapies. The market encompasses diagnostics, including imaging, biopsy, and molecular testing, as well as treatment options such as surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Technological advancements, precision medicine, and supportive regulatory frameworks are enhancing patient outcomes. Hospitals, diagnostic laboratories, and specialty cancer centers remain the primary end-users, ensuring broad adoption across healthcare settings.

Market Dynamics

Rising Global Lung Cancer Prevalence and Screening Demand

A fundamental driver of the global lung cancer diagnostics and treatment market is the increasing incidence and prevalence of lung cancer globally. Lung cancer remains one of the most common and fatal cancers, with rising case numbers attributed to smoking habits, environmental pollution (air quality), aging populations, and other risk factors. This growing disease burden fuels demand for early diagnostic solutions such as imaging (low-dose CT scans) and biomarker testing, as well as for effective therapeutic interventions, including targeted therapies and immunotherapies. The continued emphasis on early detection through screening programs, particularly in high-risk populations, also boosts the adoption of detection technologies and expands treatment pipelines.

Technological Advancements and Precision Medicine Adoption

Rapid advancements in molecular diagnostics, genomic profiling, liquid biopsy, and AI-enhanced imaging technologies are significantly driving market growth. These innovations improve diagnostic accuracy, enable earlier and less invasive detection, and support better stratification of patients for tailored treatment approaches. On the treatment side, the rise of precision medicine, including targeted therapies and immunotherapies matched to specific genetic mutations, has expanded the therapeutic landscape and improved patient outcomes, increasing the demand for both companion diagnostics and specialized treatment regimens. This technological evolution is a key factor differentiating modern lung cancer care and accelerating market expansion.

Expanded Therapeutic Options and Regulatory Support

The treatment segment is being driven by a growing arsenal of therapies from next-generation targeted drugs to immune checkpoint inhibitors and combination regimens that offer improved survival and reduced side effects compared with traditional chemotherapy. Regulatory agencies in major markets like the US and Europe have been accelerating approvals for new agents and companion diagnostic tools, enabling faster market entry and broader clinical use. Widening insurance coverage and reimbursement policies in emerging markets further enhance therapy accessibility, encouraging uptake of advanced treatment options and strengthening market momentum.

Market Segmentation

Based on the type, the market is segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Based on the diagnosis type, the market is segmented into imaging tests, biopsy, and molecular testing.
Based on the treatment type, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, and others.
Based on the end-user, the market is segmented into hospitals, diagnostic laboratories, specialty clinics/cancer centers, and others.

Non-Small Cell Lung Cancer (NSCLC) Segment to Grow at a Considerable Market Share

The non-small cell lung cancer (NSCLC) segment is expected to lead the Global Lung Cancer Diagnostics and Treatment Market over the forecast period, driven by its high prevalence and the growing demand for specialized diagnostic and therapeutic interventions. NSCLC accounts for approximately 85-90% of all lung cancer cases globally, making it the most common form of the disease. Its dominance in the market is reinforced by the increasing adoption of precision medicine, including targeted therapies and immunotherapies, which are predominantly developed for NSCLC patients due to the identification of specific genetic mutations such as EGFR, ALK, and ROS1.

In diagnostics, NSCLC patients often require a combination of imaging tests, biopsy, and molecular testing, further expanding the market for diagnostic tools and laboratory services. The rising emphasis on early detection through low-dose CT scans and liquid biopsies has increased the frequency of NSCLC diagnosis, particularly in high-risk populations such as long-term smokers and the elderly. Additionally, hospitals and specialized cancer centers are increasingly investing in advanced NSCLC treatment infrastructure, ranging from robotic surgery to precision radiation and immunotherapy suites.

The convergence of high patient volume, technological innovation in diagnostics, and a growing portfolio of effective treatments positions NSCLC as the largest and most lucrative segment within the global lung cancer diagnostics and treatment market, shaping the overall market growth trajectory and attracting significant R&D and commercial investment.

Targeted Therapy: A Key Segment in Market Growth

The targeted therapy segment under treatment type is poised as the key growth driver. Targeted therapies work by specifically attacking cancer cells based on their genetic mutations or molecular profiles, offering a more personalized and effective treatment compared to traditional chemotherapy. This precision-based approach has shown significant improvements in patient survival rates and reduced systemic side effects, which have led to greater adoption among oncologists and healthcare providers. The surge in research and development for novel targeted agents, including tyrosine kinase inhibitors (TKIs) and other molecularly guided drugs, is further fueling this segment.

Additionally, the integration of molecular testing and genomic profiling into routine diagnostic workflows enables accurate identification of patients suitable for these therapies, creating a strong synergy between diagnostics and treatment. Growing awareness among patients, coupled with supportive regulatory approvals and expanding reimbursement policies in key markets, is accelerating uptake. Emerging markets are also witnessing increased accessibility to targeted therapies, aided by the entry of biosimilars and government healthcare initiatives, further strengthening market expansion. Overall, the Targeted Therapy segment represents a critical growth engine within the global lung cancer market due to its precision, efficacy, and rising acceptance across diverse healthcare settings.

Regional Outlook

The global lung cancer diagnostics treatment market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global lung cancer diagnostics treatment market, holding a major share due to its advanced healthcare infrastructure, high adoption of cutting-edge diagnostic technologies, and strong presence of leading pharmaceutical and biotechnology companies. The country has a well-established network of hospitals, specialty cancer centers, and diagnostic laboratories that facilitate early detection and access to comprehensive treatment options, including surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. The US is also a pioneer in precision medicine, with widespread use of molecular testing and liquid biopsy techniques that enable personalized treatment plans, particularly for non-small cell lung cancer (NSCLC) patients. Robust research and development activities, supported by both government initiatives and private investments, continuously introduce innovative therapies and diagnostic tools, further consolidating the market leadership.

In addition, favorable reimbursement policies, high healthcare spending, and patient awareness about lung cancer screening programs drive strong adoption of advanced diagnostics and treatments. The combination of technological advancement, regulatory support, and a high prevalence of lung cancer cases ensures that the United States remains the largest and most influential market globally, shaping trends and setting benchmarks for lung cancer management globally.

Market Players Outlook

The major companies operating in the global lung cancer diagnostics treatment market include AstraZeneca PLC, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Pfizer Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

In January 2026, the NHS launched an innovative lung cancer diagnostic pathway in collaboration with Optellum, integrating AI-driven risk stratification and robotic-assisted bronchoscopy. This initiative, led by Guy's and St Thomas' NHS Foundation Trust, aims to enhance early and accurate diagnosis of lung cancer while minimizing invasive procedures. It expands upon the NHS Lung Cancer Screening Programme, which utilizes low-dose CT scans to detect suspicious nodules in individuals aged 55-74. The new program uniquely combines AI-based stratification to identify high-risk nodules and employs robotic bronchoscopy for precise biopsy, potentially reducing patient wait times and uncertainty through efficient diagnosis.

The Report Covers:

Market value data analysis for 2025 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global lung cancer diagnostics treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023497

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Lung Cancer Diagnostics Treatment Market Sales Analysis - Type | Diagnosis Type | Treatment Type| End-User ($ Million)
Lung Cancer Diagnostics Treatment Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Lung Cancer Diagnostics Treatment Market Trends
- 2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the Lung Cancer Diagnostics Treatment Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Lung Cancer Diagnostics Treatment Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Lung Cancer Diagnostics Treatment Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Lung Cancer Diagnostics Treatment Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Lung Cancer Diagnostics Treatment Market Revenue and Share by Manufacturers
Lung Cancer Diagnostics Treatment Diagnosis Type Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. AstraZeneca PLC
  - 4.2.1.1. Overview
  - 4.2.1.2. Diagnosis Type Portfolio
  - 4.2.1.3. Financial Analysis
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Bristol-Myers Squibb Co.
  - 4.2.2.1. Overview
  - 4.2.2.2. Diagnosis Type Portfolio
  - 4.2.2.3. Financial Analysis
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. F. Hoffmann-La Roche Ltd.
  - 4.2.3.1. Overview
  - 4.2.3.2. Diagnosis Type Portfolio
  - 4.2.3.3. Financial Analysis
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Merck & Co., Inc.
  - 4.2.4.1. Overview
  - 4.2.4.2. Diagnosis Type Portfolio
  - 4.2.4.3. Financial Analysis
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Pfizer Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Diagnosis Type Portfolio
  - 4.2.5.3. Financial Analysis
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Diagnosis Type Launch
- 4.3.3. Partnership And Collaboration

5. Global Lung Cancer Diagnostics Treatment Market Sales Analysis by Type ($ Million)

5.1. Non-Small Cell Lung Cancer (NSCLC)
5.2. Small Cell Lung Cancer (SCLC)

6. Global Lung Cancer Diagnostics Treatment Market Sales Analysis by Diagnosis Type ($ Million)

6.1. Imaging Tests
6.2. Biopsy
6.3. Molecular Testing

7. Global Lung Cancer Diagnostics Treatment Market Sales Analysis by Treatment Type ($ Million)

7.1. Surgery
7.2. Radiation Therapy
7.3. Chemotherapy
7.4. Targeted Therapy
7.5. Immunotherapy
7.6. Others

8. Global Lung Cancer Diagnostics Treatment Market Sales Analysis by End-User ($ Million)

8.1. Hospitals
8.2. Diagnostic Laboratories
8.3. Specialty Clinics / Cancer Centers
8.4. Others

9. Regional Analysis

9.1. North American Lung Cancer Diagnostics Treatment Market Sales Analysis - Type | Diagnosis Type | Treatment Type| End-User | Country ($ Million)
Macroeconomic Factors for North America
- 9.1.1. United States
- 9.1.2. Canada
9.2. European Lung Cancer Diagnostics Treatment Market Sales Analysis - Type | Diagnosis Type | Treatment Type| End-User | Country ($ Million)
Macroeconomic Factors for Europe
- 9.2.1. UK
- 9.2.2. Germany
- 9.2.3. Italy
- 9.2.4. Spain
- 9.2.5. France
- 9.2.6. Russia
- 9.2.7. Rest of Europe
9.3. Asia-Pacific Lung Cancer Diagnostics Treatment Market Sales Analysis - Type | Diagnosis Type | Treatment Type| End-User | Country ($ Million)
Macroeconomic Factors for Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. South Korea
- 9.3.4. India
- 9.3.5. Australia & New Zealand
- 9.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 9.3.7. Rest of Asia-Pacific
9.4. Rest of the World Lung Cancer Diagnostics Treatment Market Sales Analysis - Type | Diagnosis Type | Treatment Type| End-User | Country ($ Million)
Macroeconomic Factors for the Rest of the World
- 9.4.1. Latin America
- 9.4.2. Middle East and Africa

10. Company Profiles

10.1. Agilent Technologies
- 10.1.1. Quick Facts
- 10.1.2. Company Overview
- 10.1.3. Product Portfolio
- 10.1.4. Business Strategies
10.2. Amgen Inc.
- 10.2.1. Quick Facts
- 10.2.2. Company Overview
- 10.2.3. Product Portfolio
- 10.2.4. Business Strategies
10.3. AstraZeneca
- 10.3.1. Quick Facts
- 10.3.2. Company Overview
- 10.3.3. Product Portfolio
- 10.3.4. Business Strategies
10.4. Boehringer Ingelheim
- 10.4.1. Quick Facts
- 10.4.2. Company Overview
- 10.4.3. Product Portfolio
- 10.4.4. Business Strategies
10.5. Bristol-Myers Squibb Co.
- 10.5.1. Quick Facts
- 10.5.2. Company Overview
- 10.5.3. Product Portfolio
- 10.5.4. Business Strategies
10.6. Daiichi Sankyo
- 10.6.1. Quick Facts
- 10.6.2. Company Overview
- 10.6.3. Product Portfolio
- 10.6.4. Business Strategies
10.7. Eli Lilly and Co.
- 10.7.1. Quick Facts
- 10.7.2. Company Overview
- 10.7.3. Product Portfolio
- 10.7.4. Business Strategies
10.8. F. Hoffmann-La Roche Ltd.
- 10.8.1. Quick Facts
- 10.8.2. Company Overview
- 10.8.3. Product Portfolio
- 10.8.4. Business Strategies
10.9. GlaxoSmithKline (GSK)
- 10.9.1. Quick Facts
- 10.9.2. Company Overview
- 10.9.3. Product Portfolio
- 10.9.4. Business Strategies
10.10. Guardant Health
- 10.10.1. Quick Facts
- 10.10.2. Company Overview
- 10.10.3. Product Portfolio
- 10.10.4. Business Strategies
10.11. Illumina, Inc.
- 10.11.1. Quick Facts
- 10.11.2. Company Overview
- 10.11.3. Product Portfolio
- 10.11.4. Business Strategies
10.12. Johnson & Johnson
- 10.12.1. Quick Facts
- 10.12.2. Company Overview
- 10.12.3. Product Portfolio
- 10.12.4. Business Strategies
10.13. Merck & Co., Inc.
- 10.13.1. Quick Facts
- 10.13.2. Company Overview
- 10.13.3. Product Portfolio
- 10.13.4. Business Strategies
10.14. Novartis AG
- 10.14.1. Quick Facts
- 10.14.2. Company Overview
- 10.14.3. Product Portfolio
- 10.14.4. Business Strategies
10.15. Pfizer Inc.
- 10.15.1. Quick Facts
- 10.15.2. Company Overview
- 10.15.3. Product Portfolio
- 10.15.4. Business Strategies
10.16. Qiagen
- 10.16.1. Quick Facts
- 10.16.2. Company Overview
- 10.16.3. Product Portfolio
- 10.16.4. Business Strategies
10.17. Sanofi S.A.
- 10.17.1. Quick Facts
- 10.17.2. Company Overview
- 10.17.3. Product Portfolio
- 10.17.4. Business Strategies
10.18. Siemens Healthineers
- 10.18.1. Quick Facts
- 10.18.2. Company Overview
- 10.18.3. Product Portfolio
- 10.18.4. Business Strategies
10.19. Takeda Pharmaceutical
- 10.19.1. Quick Facts
- 10.19.2. Company Overview
- 10.19.3. Product Portfolio
- 10.19.4. Business Strategies
10.20. Thermo Fisher Scientific
- 10.20.1. Quick Facts
- 10.20.2. Company Overview
- 10.20.3. Product Portfolio
- 10.20.4. Business Strategies